CN105166620A - Horseradish tree composition capable of reducing blood lipid and preparation method of horseradish tree composition - Google Patents
Horseradish tree composition capable of reducing blood lipid and preparation method of horseradish tree composition Download PDFInfo
- Publication number
- CN105166620A CN105166620A CN201510442673.7A CN201510442673A CN105166620A CN 105166620 A CN105166620 A CN 105166620A CN 201510442673 A CN201510442673 A CN 201510442673A CN 105166620 A CN105166620 A CN 105166620A
- Authority
- CN
- China
- Prior art keywords
- moringa
- blood
- blood lipid
- composition
- reducing composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000011347 Moringa oleifera Nutrition 0.000 title claims abstract description 89
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 210000004369 blood Anatomy 0.000 title claims abstract description 38
- 239000008280 blood Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 244000179886 Moringa oleifera Species 0.000 title abstract description 81
- 150000002632 lipids Chemical class 0.000 title abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 27
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 17
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 16
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 15
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 15
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 15
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 15
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 15
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 15
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 15
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 15
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 15
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 101100174180 Caenorhabditis elegans fos-1 gene Proteins 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 241000220215 Moringa Species 0.000 claims 8
- 240000000171 Crataegus monogyna Species 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 239000003814 drug Substances 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 241000512259 Ascophyllum nodosum Species 0.000 abstract 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 abstract 3
- 235000011613 Pinus brutia Nutrition 0.000 abstract 3
- 241000018646 Pinus brutia Species 0.000 abstract 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract 3
- 229940107187 fructooligosaccharide Drugs 0.000 abstract 3
- 230000002153 concerted effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 54
- 241001092040 Crataegus Species 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000748 compression moulding Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000002402 anti-lipaemic effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010067997 Iodine deficiency Diseases 0.000 description 2
- 241001506371 Kadsura Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000006479 iodine deficiency Nutrition 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VVVDGSCGBGBGFN-UHFFFAOYSA-O 2-[decoxy(hydroxy)phosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C VVVDGSCGBGBGFN-UHFFFAOYSA-O 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 241000220214 Moringaceae Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- -1 lipoid Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000021018 plums Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to the technical field of health care foods, and particularly discloses a horseradish tree composition capable of reducing blood lipid and a preparation method of the horseradish tree composition. The composition is prepared from the following raw materials in percentage by weight: 20-80% of horseradish tree leaves, 1-20% of Chinese magnoliavine fruits, 1-20% of pine pollen, 1-20% of haws, 1-20% of kelp and 1-20% of fructo-oligosaccharide. The horseradish tree leaves, the haws and the kelp contain effective components for reducing blood lipid, so that the composition has the health care function of reducing blood lipid; the Chinese magnoliavine fruits, the pine pollen, the haws, the kelp and the fructo-oligosaccharide have the function of regulating the metabolism of human bodies, and the blood lipid of the human bodies can be reduced through indirect action, so that the composition has the effect of reducing blood lipid efficiently. The horseradish tree leaves are a sovereign drug, the Chinese magnoliavine fruits are a minister drug, the pine pollen and the haws are assistant drugs, the kelp and the fructo-oligosaccharide are envoy drugs, and all the raw materials have synergetic concerted application effects, so that the composition has a remarkable effect of reducing blood lipid. The preparation method disclosed by the invention is simple and convenient to operate and suitable for industrialized application.
Description
Technical field
The present invention relates to health food processing technique field, be specifically related to a kind of Moringa blood-fat reducing composition and preparation method thereof.
Background technology
Moringa, Capparales Moringaceae, originate in India, be also called drumstick tree, it is perennial tropical deciduous tree, about there are 14 kinds in the whole world, and kind comparatively normal edible at present has following three kinds: India's tradition Moringa, India's improvement kind of Moringa (the improvement kind of T.N. agriculture university of India, early raw and tool high pod yield) and African Moringa (former originates in the neighbouring and Ethiopia west and south of Kenya's Turkana Lake).Blade and the fruit pod of Moringa contain several mineral materials, vitamin, 20 seed amino acids, 46 kinds of antioxygen elements, 36 kinds of naturally anti-scorching bodies and mineral matters.Research shows, the vitamin e content in the fresh blade of 100 grams of India's tradition Moringas is about 9 milligrams, and in dry blade, vitamin e content is about 16.2 milligrams.The vitamin C contained in the Moringa of every 100 grams is 7 times of oranges and tangerines, and iron is 3 times of spinach, and vitamin A is 4 times of carrot, and calcareous is 4 times of milk, and potassium is 3 times of banana, and protein is 2 times of Yoghourt.According to calculating, if the leaf of Moringa dry powder of three soupspoons (about 25 grams) just containing needed for child every day 270% vitamin A, the protein of 42%, the calcium of 125%, the iron of 70% and the vitamin C of 22%.For the women in conceived and lactation, Moringa blade and beanpod also can help me and fetus or baby to remain healthy, provide a large amount of ironys, protein, copper, sulphur and vitamin B.
Because Moringa contains abundant nutritional labeling; the function of augment nutritional, Dietotherapy health is had as raw-food material; can activating cell develop immunitypty; contribute to excreting insulin and regulate blood sugar; anti-oxidant, Green Tea Extract, elimination human body active oxygen effectively; have abundant health care's effect, long-term taking for antihypertensive, high fat of blood falls, reducing hyperglycaemia has positive effect, can anti-cancer, anti-curing oncoma, develop immunitypty, cardioprotection, prophylactic treatment diabetes in advance.And due to the above-mentioned health-care efficacy of Moringa, be that the health food of raw material emerges in large numbers gradually with Moringa, as Chinese patent CN1903232A discloses a kind of moringa powder nutriment, the component of its percentage by weight is the oil Drumstick Tree powder powder of 1% ~ 99% and the XIABANLAMU powder of 99% ~ 1%, oil Drumstick Tree powder powder and XIABANLAMU powder by the leaf of oil Drumstick Tree powder, flower, really, seed and spray pulverize after powder mix in any proportion and form.The nutriment of the disclosure has good step-down, lipopenicillinase, hypoglycemic, antitumor, strengthen the medical health effects such as body immunity, but the nutriment due to the disclosure has multiple health care lacks specific aim, cause the health-care effect for a certain effect very not remarkable, effect such as reducing blood lipid is remarkable not, but now along with the raising of people's living standard, there is the sub-health state of Hyperlipemia in increasing people, people are in the urgent need to a food having lipid-lowering effect concurrently, play the health-care effect of reducing blood lipid in daily life, but the health food of current with Moringa is raw material or nutriment all form according to mouthfeel and nutrition arrangement, there is multiple health care, lack specific aim, effect for reducing blood lipid is remarkable not, the daily health caring demand of people with hyperlipidemia now can not be met, therefore a kind of product with remarkable blood fat reducing function based on Moringa is researched and developed, the economic worth of the sub-health status and raising Moringa that improve people's high fat of blood is all had great importance.
Summary of the invention
In order to overcome the defect of prior art, an object of the present invention is to provide a kind of Moringa blood-fat reducing composition, has significant antilipemic healthy effect.
Meanwhile, the present invention is also the preparation method providing a kind of Moringa blood-fat reducing composition.
In order to realize above object, the technical solution adopted in the present invention is as follows:
A kind of Moringa blood-fat reducing composition, is made up of the raw material of following weight percentage: leaf of Moringa 20 ~ 80%, the fruit of Chinese magnoliavine 1 ~ 20%, pollen pini 1 ~ 20%, hawthorn 1 ~ 20%, sea-tangle 1 ~ 20%, FOS 1 ~ 20%.
Preferably, described leaf of Moringa is Moringa young stem and leaf.
Each raw material abbreviated functional description:
Leaf of Moringa is rich in several mineral materials, vitamin, 20 seed amino acids, 46 kinds of antioxygen elements, 36 kinds of naturally anti-scorching bodies and mineral matters, can activating cell develop immunitypty, effectively anti-oxidant, Green Tea Extract, elimination human body active oxygen, long-term taking is for hypotensive, reducing blood lipid and hypoglycemicly have obvious effect.
The fruit of Chinese magnoliavine (profound and, meeting and, five plums) point fructus schisandrae and kadsura longepedunculata, fructus schisandrae matter is more excellent than kadsura longepedunculata.Fruit of Chinese magnoliavine happiness subacidity fertile soil, needs enough moisture and nutrition growth period, is distributed in the ground such as Heilungkiang, Jilin, Liaoning, the Inner Mongol, Hebei.The fruit of Chinese magnoliavine is containing volatile ingredient, lignanoids and organic acid, also containing citral (Citrdal), chlorophyll, sterol, vitamin C, vitamin E, carbohydrate, resin and tannin, have astringe the lung, nourshing kidney, promote the production of body fluid, receive sweat, puckery essence effect, cure mainly that the deficiency syndrome of the lung is breathed with cough, dry do thirsty, spontaneous perspiration, night sweat, internal lesion caused by overexertion are thin thin, emission, rushes down protracted dysentery for a long time.
Pollen pini taste is sweet, warm in nature, returns spleen, Liver Channel.There is effect of dispel the wind beneficial gas, hygroscopic, hemostasis, cure mainly head rotten, the traumatic bleeding that revolves that dizzy, middle void has a stomach-ache, protracted dysentery, all sores wet.Pollen pini, with the nutrition library of its pure natural, enhances metabolism, have adjusted incretory, has mobilized substituting excretion, has also improved the situation of heart, blood, blood vessel, served health-care effect to cardiovascular.As the magnesium in pollen pini both can kinase system, can be used as again the carrier of various nutriment; Flavonoid substances can obviously reduce blood fat and cholesterol; Various vitamin can increase vessel wall elasticity, improves the microcirculation of heart and brain.
Hawthorn, containing multivitamin, crataegolic acid, tartaric acid, citric acid, malic acid etc., also contains the mineral matter such as flavonoids, lipoid, carbohydrate, protein, fat and calcium, phosphorus, iron.Normal food hawthorn can hemangiectasis, reduce blood sugar, reduce blood pressure, prevention and cure of cardiovascular disease and senile heart disease.Utilize Fructus Crataegi disease therapy, have long history in China.Tang Materia Medica is remembered: juice takes sealing dysentery; Compendium of Material Medica remember: hawthornization diet, the meat that disappears is stagnant, all weakness of the spleen and the stomach, food indigestion, chest abdomen acid thorn swollen vexed person, chew after meals two or three piece excellent.The functions such as the traditional Chinese medical science is thought, hawthorn has more and promotes the production of body fluid to quench thirst, promoting blood circulation and removing blood stasis.And medicine physics and chemistry research in modern age to find that the medical value of hawthorn penetrates into blood blood fat field more obvious.
The sea-tangle element be rich in sea-tangle is polysaccharide, and laminarin is similar to heparin, has the effect reducing blood fat.The several mineral materials contained in sea-tangle, trace element etc., can reduce the deposition of animal tallow on heart, blood vessel, intestines wall that human body is taken in.The abundant I contained in sea-tangle is the nutrient of needed by human.If iodine deficiency can cause thyroid gland not enough, the basal metabolic rate of health is reduced, and serious iodine deficiency can cause low-level Energy transmission thus bring out obesity, and sea-tangle has good effect to the obesity that hypothyroidism causes.
FOS is a kind of water-soluble dietary fiber, and long-term taking can reduce serum cholesterol, improves lipid-metabolism.Confirm through the experiment of animal and human's body, FOS has regulating intestinal canal flora, and the effect of propagation Bifidobacterium, Bifidobacterium breeds 10 ~ 100 times under the effect of FOS.After human body takes in FOS, in body, profitable strain bifidobacteria can suppress intrinsic putrefactivebacteria in external source pathogenic bacteria and intestines as growth and breedings such as salmonellas, to reduce growth and the accumulation of corrupt substance in intestines, promote intestines peristalsis, prevent constipation and diarrhoea.FOS can effectively reduce serum cholesterol, triglycerides (?), the quantity of free fatty, a series of angiocardiopathies such as the hypertension caused because blood fat is high, artery sclerosis are had a better role.FOS is generated Pfansteihl by bacterial fermentation in large intestine, can the mineral matter such as dissolving calcium, magnesium, iron, promotes that human body is to the absorption of mineral matter.Meanwhile, FOS is a kind of well binding agent, thus avoids the binding agent of the toxic side effect adding other.
Moringa blood-fat reducing composition of the present invention, with leaf of Moringa, the fruit of Chinese magnoliavine, pollen pini, hawthorn, sea-tangle and FOS for raw material is prepared from.Leaf of Moringa, hawthorn and sea-tangle contain the active ingredient of reducing blood lipid, have the health care of reducing blood lipid; The fruit of Chinese magnoliavine, pollen pini, hawthorn, sea-tangle and FOS have the function of adjustment human metabolism, reduce human body blood fat, thus play the effect of efficient reducing blood lipid by indirectly-acting.Moringa blood-fat reducing composition of the present invention, follow the theory of traditional Chinese medical science that monarch works in coordination with compatibility, limit the consumption of each raw material, each raw material is acted synergistically in the amount ranges limited, be specially: leaf of Moringa is monarch drug in a prescription, promote body metabolism by materials such as excess fats in removing human vas and tissue, thus promote fat metabolism, reduce human body serum lipid concentrations; The fruit of Chinese magnoliavine is ministerial drug, strengthens the operation of the five internal organs of human body, allows the operation of human five internal organs more coordinate; Pollen pini is adjutant, can promote that body metabolism is accelerated; Sea-tangle makes medicine; Hawthorn not only has softening blood vessel, reduces effect of blood fat, also has the effect promoting that human consumption absorbs, promotes the absorption of various drug ingedient, also play the effect of adjutant; FOS makes medicine, has promotion toxin expelling, the effect of adjustment human body alimentary canal Tiny ecosystem, the absorption of absorption and minimizing fat.By the collaborative compatibility effect of above-mentioned each raw material, composition is made to have significant effect for reducing blood fat.
Moringa blood-fat reducing composition of the present invention has the function reducing efficiently blood fat, can some special blood lipid-lowering medicines of Some substitute, and the treatment of auxiliary people with hyperlipidemia and prevention, reduce the toxic and side effect using special blood lipid-lowering medicine to bring.
Above-mentioned each raw material is preferably Powdered.
The formulation of above-mentioned Moringa blood-fat reducing composition is tablet.
Above-mentioned Moringa blood-fat reducing composition can be also other medically acceptable formulations, as granule, capsule, pulvis, oral liquid etc., and adopts the customary preparation methods of pharmaceutical formulating art can obtain the Moringa blood-fat reducing composition of other formulations.
The preparation method that above-mentioned Moringa blood-fat reducing composition makes tablet is comprise and each raw material is mixed rear compressing tablet, dry, obtains described Moringa blood-fat reducing composition.
Preferably, also comprise each raw material to pulverize and mix again after Powdered.
Described drying is for being dried to water content lower than 10%.
The preparation method of Moringa blood-fat reducing composition of the present invention, adopts mode shaping for direct tablet compressing after each raw material mixing, easy and simple to handle, is easy to realize, is convenient to industrial application.
Detailed description of the invention
Below by specific embodiment, technical scheme of the present invention is described in detail.
In following embodiment, Moringa blood-fat reducing composition is tablet, but this formulation does not form any limitation of the invention, and the change of formulation does not affect the health-care effect of Moringa blood-fat reducing composition of the present invention.
Embodiment 1
The present embodiment Moringa blood-fat reducing composition, its formulation is tablet, is made up of the raw material of following weight percentage: leaf of Moringa 40%, the fruit of Chinese magnoliavine 10%, pollen pini 10%, hawthorn 10%, sea-tangle 10%, FOS 20%.
The preparation method of the present embodiment Moringa blood-fat reducing composition, concrete operation step is:
1) getting each raw meal is broken into Powdered;
2) by after pulverous each raw material mixing and stirring, compression molding, is dried to water content lower than 10%, obtains described Moringa blood-fat reducing composition.
Moringa reducing blood lipid tablet prepared by the present embodiment, the weight of average every sheet is 0.7g.
Embodiment 2
The present embodiment Moringa blood-fat reducing composition, its formulation is tablet, is made up of the raw material of following weight percentage: leaf of Moringa 20%, the fruit of Chinese magnoliavine 20%, pollen pini 20%, hawthorn 10%, sea-tangle 20%, FOS 10%.
The preparation method of the present embodiment Moringa blood-fat reducing composition, concrete operation step is:
1) getting each raw meal is broken into Powdered;
2) by after pulverous each raw material mixing and stirring, compression molding, is dried to water content lower than 10%, obtains described Moringa blood-fat reducing composition.
Moringa reducing blood lipid tablet prepared by the present embodiment, the weight of average every sheet is 0.7g.
Embodiment 3
The present embodiment Moringa blood-fat reducing composition, its formulation is tablet, is made up of the raw material of following weight percentage: leaf of Moringa 55%, the fruit of Chinese magnoliavine 1%, pollen pini 15%, hawthorn 20%, sea-tangle 8%, FOS 1%.
The preparation method of the present embodiment Moringa blood-fat reducing composition, concrete operation step is:
1) getting each raw meal is broken into Powdered;
2) by after pulverous each raw material mixing and stirring, compression molding, is dried to water content lower than 10%, obtains described Moringa blood-fat reducing composition.
Moringa reducing blood lipid tablet prepared by the present embodiment, the weight of average every sheet is 0.7g.
Embodiment 4
The present embodiment Moringa blood-fat reducing composition, its formulation is tablet, is made up of the raw material of following weight percentage: leaf of Moringa 80%, the fruit of Chinese magnoliavine 8%, pollen pini 1%, hawthorn 1%, sea-tangle 1%, FOS 9%.
The preparation method of the present embodiment Moringa blood-fat reducing composition, concrete operation step is:
1) getting each raw meal is broken into Powdered;
2) by after pulverous each raw material mixing and stirring, compression molding, is dried to water content lower than 10%, obtains described Moringa blood-fat reducing composition.
Moringa reducing blood lipid tablet prepared by the present embodiment, the weight of average every sheet is 0.7g.
Comparative example
This comparative example Moringa blood-fat reducing composition is made up of the raw material of following weight percentage: leaf of Moringa 90%, xylitol 5%, FOS 5%.The method same according to embodiment is prepared into tablet.
Test example
Test method: by 50 blood fat all higher than normal value and the suitable overweight people of total cholesterol level is divided into two groups at random; Wherein one group of Moringa blood-fat reducing composition taken the embodiment of the present invention 1 and prepare; Other one group of Moringa blood-fat reducing composition taken comparative example and prepare; The T-CHOL observing two groups of hyperlipemic patients reduces situation.
Usage and dosage: everyone, each serving with three, one day twice, takes two months continuously.
Result of the test: the total cholesterol level taking the overweight people of Moringa blood-fat reducing composition prepared by embodiment 1 on average reduces 1.3mmol/L, weight average reduces about 2.5 kilograms; The total cholesterol level taking the overweight people of Moringa blood-fat reducing composition prepared by comparative example on average reduces 0.47mmol/L, and weight average reduces about 1.2 kilograms.
From above-mentioned result of the test, the antilipemic healthy effect of Moringa blood-fat reducing composition prepared by the embodiment of the present invention 1 is better than Moringa blood-fat reducing composition prepared by comparative example.This result shows, in Moringa blood-fat reducing composition of the present invention, by adding the fruit of Chinese magnoliavine, pollen pini, hawthorn, sea-tangle and FOS and leaf of Moringa carries out composite, improves antilipemic healthy effect of composition.
The blood fat reducing function of Moringa blood-fat reducing composition prepared by embodiment 2 ~ 4 is suitable with embodiment 1.
Claims (6)
1. a Moringa blood-fat reducing composition, is characterized in that, is made up of the raw material of following weight percentage: leaf of Moringa 20 ~ 80%, the fruit of Chinese magnoliavine 1 ~ 20%, pollen pini 1 ~ 20%, hawthorn 1 ~ 20%, sea-tangle 1 ~ 20%, FOS 1 ~ 20%.
2. Moringa blood-fat reducing composition as claimed in claim 1, it is characterized in that, described raw material is Powdered.
3. Moringa blood-fat reducing composition as claimed in claim 1, it is characterized in that, its formulation is tablet.
4. a preparation method for Moringa blood-fat reducing composition as claimed in claim 1, is characterized in that, comprises and each raw material is mixed rear compressing tablet, dry, obtains described Moringa blood-fat reducing composition.
5. the preparation method of Moringa blood-fat reducing composition as claimed in claim 4, is characterized in that, also comprises and each raw material pulverizing being mixed after Powdered again.
6. the preparation method of Moringa blood lipid-lowering composite as claimed in claim 4, it is characterized in that, described drying is for being dried to water content lower than 10%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510442673.7A CN105166620A (en) | 2015-07-24 | 2015-07-24 | Horseradish tree composition capable of reducing blood lipid and preparation method of horseradish tree composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510442673.7A CN105166620A (en) | 2015-07-24 | 2015-07-24 | Horseradish tree composition capable of reducing blood lipid and preparation method of horseradish tree composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105166620A true CN105166620A (en) | 2015-12-23 |
Family
ID=54889470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510442673.7A Pending CN105166620A (en) | 2015-07-24 | 2015-07-24 | Horseradish tree composition capable of reducing blood lipid and preparation method of horseradish tree composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105166620A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617049A (en) * | 2016-09-29 | 2017-05-10 | 广州市汇吉科技企业孵化器有限公司 | Propolis healthcare product with moringa oleifera leaf extract and method for preparing propolis healthcare product |
| CN110419724A (en) * | 2019-08-27 | 2019-11-08 | 贵州木辣达康养科技有限公司 | A kind of horseradish tree chawing tablet and its processing method of the ease constipation that has effects that help digestion |
| CN112841626A (en) * | 2021-01-18 | 2021-05-28 | 优杨格股份有限公司 | Moringa oleifera leaf probiotic powder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104622922A (en) * | 2015-02-10 | 2015-05-20 | 湖州健泰食品有限公司 | Horseradish tree leaf tablet and preparation method thereof |
-
2015
- 2015-07-24 CN CN201510442673.7A patent/CN105166620A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104622922A (en) * | 2015-02-10 | 2015-05-20 | 湖州健泰食品有限公司 | Horseradish tree leaf tablet and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 南京中医药大学: "《中药大辞典》", 30 March 2006, 上海科学技术出版社 * |
| 柴瑞震: "《糖尿病中医食养方》", 31 January 2014, 江西科学技术出版社 * |
| 王唯: "《健康食用主义》", 30 April 2009, 江西科学技术出版社 * |
| 甘智荣: "《日常饮食宜忌速查100例》", 30 June 2015, 重庆出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617049A (en) * | 2016-09-29 | 2017-05-10 | 广州市汇吉科技企业孵化器有限公司 | Propolis healthcare product with moringa oleifera leaf extract and method for preparing propolis healthcare product |
| CN110419724A (en) * | 2019-08-27 | 2019-11-08 | 贵州木辣达康养科技有限公司 | A kind of horseradish tree chawing tablet and its processing method of the ease constipation that has effects that help digestion |
| CN112841626A (en) * | 2021-01-18 | 2021-05-28 | 优杨格股份有限公司 | Moringa oleifera leaf probiotic powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940155B (en) | Duckling feed for cherry valley duck and preparation method thereof | |
| CN104855967A (en) | Non-whole nutrient formula food for patients having obesity or fat-reducing surgery | |
| CN101878908A (en) | Seabuckthorn fruit extract combined health care products and preparation method thereof | |
| CN103053987B (en) | Pumpkin flavor granular condiment | |
| CN105124347A (en) | Moringa oleifera blood-glucose-reducing composition and preparation method thereof | |
| CN104305207A (en) | Formula of traditional Chinese medicine composite ferment and preparing method thereof | |
| CN103918901A (en) | Preparation method for suckling piglet Chinese herb health premix | |
| CN103478200A (en) | Rose and purple sweet potato biscuit | |
| CN107303280A (en) | Okra chews tablet composition and preparation method thereof | |
| CN107173656A (en) | A kind of Chinese medicine fruits and vegetables probiotics fermented beverage and preparation method thereof | |
| CN105384562A (en) | Pleurotus geesteranus medium | |
| CN104839695A (en) | Inflammatory bowel disease non-total nutrient formula food | |
| CN104839698A (en) | Cardiovascular disease non-total nutrient formula food | |
| CN104872638A (en) | Non-total nutrient formula food for constipation patients | |
| CN105166620A (en) | Horseradish tree composition capable of reducing blood lipid and preparation method of horseradish tree composition | |
| CN104957474A (en) | Moringa oleifera composition for reducing blood pressure and preparation method of moringa oleifera composition | |
| CN103518878B (en) | Honey vinegar beverage with function of lubricating intestines and invigorating stomach and preparation method thereof | |
| CN105341300A (en) | Health-care candies suitable for children to eat | |
| CN102511876B (en) | Hawthorn red jujube thick syrup and production process thereof | |
| CN104938900A (en) | Moringa hangover-alleviating composition and preparation method thereof | |
| CN101797049B (en) | Nutrient eight-treasure soup formula and preparation process thereof | |
| CN103271353B (en) | Liver protecting and health care composition and preparation method thereof | |
| CN105497106A (en) | Traditional Chinese medicine compound fermentation powder and preparation method thereof | |
| CN104839699A (en) | Heart disease non-total nutrient formula food | |
| CN104054931A (en) | Fruit-aroma-flavored compound feed for meat ducks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151223 |